Table 1 Characteristics of the included studies
Author, Year | Country | Patients (number, sex, age) | Histology, Stage, Treatment | QOL | QOL domains | Follow-up period | Confounders | Number of deaths |
|---|---|---|---|---|---|---|---|---|
Badaoui S et al., [30]2022 | Australia | n = 2892 Female, 33% Age: 64 (58–70) years | NSCLC, Stage IV, Chemotherapy | EORTC QLQ-C30 | Global Physical Emotional Role Cognitive Social | Median: 18 months | age, sex, race, ECOG-PS, smoking history, histology, PD-L1 expression　level, comorbidity | Not reported |
Erdem R et al., [29] 2022 | Turkey | n = 50 Female, 8% Age: 55.9 (Min: 36, Max: 80) years | NSCLC, Stage IIIB and IV, Chemotherapy | EORTC QLQ-C30 | Global Physical Emotional Role Cognitive Social | single-agent chemotherapy: 272 days combination chemotherapy: 445 days | Single or combination chemotherapy, Constipation, other QOL domains, Fatigue, Dyspnea, Insomnia | Not reported |
Fielding R et al., [35] 2007 | Hong Kong | n = 358 Female, 24.3% Age: 64.81 ± 10.28 years | SCLC n = 39 NSCLC n = 288 bronchogenic carcinoma n = 31, Stage 1- IV, Not reported | FACT-G | Global Physical Emotional Social | 25 months | Histology, sociodemographic variables | n = 246 |
Langendijk H et al., [31] 2000 | Netherlands | n = 198 Female, 15% Age: 0–70 years, 51% | NSCLC, Stage 1- IIIB, Radiation therapy | EORTC QLQ-C30 | Global Physical Emotional Role Cognitive Social | Median survival 0 risk factors: 16.2 months 1 risk factor: 10.9 months 2 risk factors: 8.3 months | N-classification, weight loss and WHO performance status | Not reported |
Movsas B et al., [32] 2009 | USA | n = 239 Female, 31.8% Age: ≦70 years (70.7%)  > 70 years (12.9%) | NSCLC, Stage II- IIIB, Chemoradiation therapy | EORTC QLQ-C30 | Global Physical | 5 years | age, treatment arm, karnofsky PS, histology, gender, tumor location, martial status, race, AJCC stage, hemoglobin, smoking status | Not reported |
Möller A et al., [39] 2012 | Sweden | n = 141 Female, 54% Age: 66.6 ± 9.1 | NSCLC n,114 Carcinoid n = 15 Other n = 12, Stage 1- III, Surgery | SF-36 | Physical Role Social | 3 years | age, gender, comorbidities, extent of resection, tumor stage, smoking status, postoperative complications, | n = 53 |
Nieto-Guerrero Gómez JM et al., [36] 2020 | Spain | n = 437 Female, 14% Age: 66 (range 31–88) years | NSCLC n = 297 SCLC n = 122 Others n = 18, Stage 1- IV Surgery n = 51, Radiation Therapy n = 378 Chemotherapy n = 382 Chemoradiation therapy n = 163 | EORTC QLQ-C30 | Global Physical Emotional Role Cognitive Social | 30 months (range 7–76) | other QOL domains | Not reported |
Pinheiro LC et al., [37] 2018 | USA | n = 535 Female, 50% Age: 75 years | NSCLC n = 484 SCLC n = 51 Local n = 182, Regional n = 182, Distant/unknown n = 171, Surgery n = 241 Radiation therapy n = 182 | SF-36 | Physical Role Social | 2 years | MCS, PCS, Physical function, General health, Role physical, Role emotional, Mental health, Social function, Body pain, Vitality | n = 300 |
Pompili C et al., [33] 2022 | UK | n = 388 Female, 51% Age: 68.9 ± 9.6 years | NSCLC, pathologically R0 resections, Surgery | EORTC QLQ-C30 | Global Physical Emotional Role Cognitive Social | Median follow-up: 55 months (IQR: 42–66) | age, BMI, gender, pathologic stage, DLCO | n = 120 |
Reck M et al., [34] 2012 | Germany | n = 238 Female, not reported Age: not reported | SCLC, Extensive disease, Chemotherapy | FACT-G | Physical | Not reported | FACT-G and FACT subscale scores, age, gender, lactate dehydrogenase, number of metastatic sites, history of brain metastases, and ECOG PS | n = 87 |
Trejo MJ et al., [38] 2020 | Australia | n = 111 Female, 45% Age: 64 (34–80) years | NSCLC n = 106 SCLC n = 5, Stage III and IV, Chemotherapy | EORTC QLQ-C30 | Global Physical Emotional Role Cognitive Social | Not reported | sex, age, randomization arm | Not reported |